Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Rare and Inherited Diseases›Acrodermatitis
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Acrodermatitis

Rare and Inherited Diseases · NLM MeSH · updated 2026-10-29 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 5 min read

Inflammation involving the skin of the extremities, especially the hands and feet.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (895 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

Inflammation involving the skin of the extremities, especially the hands and feet. Several forms are known, some idiopathic and some hereditary. The infantile form is called Gianotti-Crosti syndrome.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Acrodermatitides; Gianotti-Crosti Syndrome; Gianotti Crosti Syndrome; Syndrome, Gianotti-Crosti; Acrodermatitis Papulosa Infantum; Acrodermatitis Papulosa Infantums; Acropapulo-Vesicular Syndrome; Acropapulo Vesicular Syndrome.

Where it fits in the MeSH classification

Broader topics
Skin Abnormalities; Dermatitis

Research landscape

PubMed indexes 2,357 records tagged with the MeSH heading “Acrodermatitis” (counts retrieved 2026-10-29). 160 of them (6.8%) were published from 2020 onward, and the busiest period so far is through 1999 with 1,564 records.

Reviews account for 278 records (11.8%) and meta-analyses for 1. Randomized controlled trials number 1 (0.0%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 1,564 records; 2000-2009: 300 records; 2010-2019: 333 records; 2020 onward: 160 records1,564through 19993002000-20093332010-20191602020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 19991,564
2000-2009300
2010-2019333
2020 onward160
Share of records by publication typeReviews: 11.8 percent; Meta-analyses: 0.0 percent; Randomized controlled trials: 0.0 percentReviews11.8% (278)Meta-analyses0.0% (1)Randomized controlled trials0.0% (1)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 2,357 PubMed records
TypeRecordsShare
Reviews27811.8%
Meta-analyses10.0%
Randomized controlled trials10.0%

Method: PubMed query "Acrodermatitis"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.

Reading the evidence in rare and inherited diseases

Rare conditions are difficult to study: few patients means small studies, case reports and registries are common, and randomized trials are the exception. Small samples limit precision and can exaggerate effects, and cases reported in the literature may be the most severe or unusual. Evidence from many small studies is best read together. Check how patients were identified, how many were included and how long they were followed.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Role of zinc in health and disease
Stiles LI, Ferrao K, Mehta KJ
2024Review article
Design not recorded in structured metadata
163cc by
PMID 38367035 · DOI · PMC10874324
Vimentin filament organization and stress sensing depend on its single cysteine residue and zinc binding
Pérez-Sala D, Oeste CL, Martínez AE, Carrasco MJ, Garzón B, Cañada FJ
2015Research article
Design not recorded in structured metadata
134cc by
PMID 26031447 · DOI · PMC4458873
A mouse model of acrodermatitis enteropathica: loss of intestine zinc transporter ZIP4 (Slc39a4) disrupts the stem cell niche and intestine integrity
Geiser J, Venken KJ, De Lisle RC, Andrews GK
2012Research article
Design not recorded in structured metadata
112cc by
PMID 22737083 · DOI · PMC3380849
Case Report: Periungual Xeligekimab injection for refractory Acrodermatitis continua of Hallopeau
Cao P, Yuan A, Yang J, Zhang Y, Guo T, Li C
2026Research article
Design not recorded in structured metadata
1cc by
PMID 41853264 · DOI · PMC12992313

Role of zinc in health and disease [1]

Review article Stiles LI, Ferrao K, Mehta KJ · · 2024 · cited 163 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
This review provides a concise overview of the cellular and clinical aspects of the role of zinc, an essential micronutrient, in human physiology and discusses zinc-related pathological states.
Closing excerpt
Notably, oral zinc supplementation may decrease the absorption of drugs like ciprofloxacin, doxycycline and risedronate.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (251 words)

This review provides a concise overview of the cellular and clinical aspects of the role of zinc, an essential micronutrient, in human physiology and discusses zinc-related pathological states. Zinc cannot be stored in significant amounts, so regular dietary intake is essential. ZIP4 and/or ZnT5B transport dietary zinc ions from the duodenum into the enterocyte, ZnT1 transports zinc ions from the enterocyte into the circulation, and ZnT5B (bidirectional zinc transporter) facilitates endogenous zinc secretion into the intestinal lumen. Putative promoters of zinc absorption that increase its bioavailability include amino acids released from protein digestion and citrate, whereas dietary phytates, casein and calcium can reduce zinc bioavailability. In circulation, 70% of zinc is bound to albumin, and the majority in the body is found in skeletal muscle and bone. Zinc excretion is via faeces (predominantly), urine, sweat, menstrual flow and semen. Excessive zinc intake can inhibit the absorption of copper and iron, leading to copper deficiency and anaemia, respectively. Zinc toxicity can adversely affect the lipid profile and immune system, and its treatment depends on the mode of zinc acquisition. Acquired zinc deficiency usually presents later in life alongside risk factors like malabsorption syndromes, but medications like diuretics and angiotensin-receptor blockers can also cause zinc deficiency. Inherited zinc deficiency condition acrodermatitis enteropathica, which occurs due to mutation in the SLC39A4 gene (encoding ZIP4), presents from birth. Treatment involves zinc supplementation via zinc gluconate, zinc sulphate or zinc chloride. Notably, oral zinc supplementation may decrease the absorption of drugs like ciprofloxacin, doxycycline and risedronate.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 38367035 · DOI · PMC10874324

Vimentin filament organization and stress sensing depend on its single cysteine residue and zinc binding [2]

Research article Pérez-Sala D, Oeste CL, Martínez AE, Carrasco MJ, Garzón B, Cañada FJ · · 2015 · cited 134 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
The vimentin filament network plays a key role in cell architecture and signalling, as well as in epithelial-mesenchymal transition.
Closing excerpt
These results unveil a critical role of C328 in vimentin organization and open new perspectives for the regulation of intermediate filaments by zinc.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (150 words)

The vimentin filament network plays a key role in cell architecture and signalling, as well as in epithelial-mesenchymal transition. Vimentin C328 is targeted by various oxidative modifications, but its role in vimentin organization is not known. Here we show that C328 is essential for vimentin network reorganization in response to oxidants and electrophiles, and is required for optimal vimentin performance in network expansion, lysosomal distribution and aggresome formation. C328 may fulfil these roles through interaction with zinc. In vitro, micromolar zinc protects vimentin from iodoacetamide modification and elicits vimentin polymerization into optically detectable structures; in cells, zinc closely associates with vimentin and its depletion causes reversible filament disassembly. Finally, zinc transport-deficient human fibroblasts show increased vimentin solubility and susceptibility to disruption, which are restored by zinc supplementation. These results unveil a critical role of C328 in vimentin organization and open new perspectives for the regulation of intermediate filaments by zinc.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 26031447 · DOI · PMC4458873

A mouse model of acrodermatitis enteropathica: loss of intestine zinc transporter ZIP4 (Slc39a4) disrupts the stem cell niche and intestine integrity [3]

Research article Geiser J, Venken KJ, De Lisle RC, Andrews GK · · 2012 · cited 112 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Mutations in the human Zip4 gene cause acrodermatitis enteropathica, a rare, pseudo-dominant, lethal genetic disorder.
Closing excerpt
These changes, in turn, cause a switch from anabolic to catabolic metabolism and altered homeostasis of several essential metals, which, if untreated by excess dietary zinc, leads to dramatic weight loss and death.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (275 words)

Mutations in the human Zip4 gene cause acrodermatitis enteropathica, a rare, pseudo-dominant, lethal genetic disorder. We created a tamoxifen-inducible, enterocyte-specific knockout of this gene in mice which mimics this human disorder. We found that the enterocyte Zip4 gene in mice is essential throughout life, and loss-of-function of this gene rapidly leads to wasting and death unless mice are nursed or provided excess dietary zinc. An initial effect of the knockout was the reprogramming of Paneth cells, which contribute to the intestinal stem cell niche in the crypts. Labile zinc in Paneth cells was lost, followed by diminished Sox9 (sex determining region Y-box 9) and lysozyme expression, and accumulation of mucin, which is normally found in goblet cells. This was accompanied by dysplasia of the intestinal crypts and significantly diminished small intestine cell division, and attenuated mTOR1 activity in villus enterocytes, indicative of increased catabolic metabolism, and diminished protein synthesis. This was followed by disorganization of the absorptive epithelium. Elemental analyses of small intestine, liver, and pancreas from Zip4-intestine knockout mice revealed that total zinc was dramatically and rapidly decreased in these organs whereas iron, manganese, and copper slowly accumulated to high levels in the liver as the disease progressed. These studies strongly suggest that wasting and lethality in acrodermatitis enteropathica patients reflects the loss-of-function of the intestine zinc transporter ZIP4, which leads to abnormal Paneth cell gene expression, disruption of the intestinal stem cell niche, and diminished function of the intestinal mucosa. These changes, in turn, cause a switch from anabolic to catabolic metabolism and altered homeostasis of several essential metals, which, if untreated by excess dietary zinc, leads to dramatic weight loss and death.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 22737083 · DOI · PMC3380849

Case Report: Periungual Xeligekimab injection for refractory Acrodermatitis continua of Hallopeau [4]

Research article Cao P, Yuan A, Yang J, Zhang Y, Guo T, Li C · · 2026 · cited 1 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
This case report presents the novel and successful use of periungual Xeligekimab injections for managing refractory Acrodermatitis Continua of Hallopeau (ACH), representing the first documented application of this localized administration route for the IL-17A inhibitor.
Closing excerpt
Concurrently, the Dermatology Life Quality Index and pain scores dramatically improved, and follow-up MRI showed substantial resolution of the underlying bone marrow edema, confirming the treatment's efficacy on both cutaneous and deep osseous inflammation.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (219 words)

This case report presents the novel and successful use of periungual Xeligekimab injections for managing refractory Acrodermatitis Continua of Hallopeau (ACH), representing the first documented application of this localized administration route for the IL-17A inhibitor. It contributes to the scientific literature by demonstrating a promising alternative therapeutic strategy for treatment-resistant ACH, highlighting the potential for enhanced local efficacy and minimized systemic exposure. The patient was a 36-year-old woman with a two-decade history of ACH affecting her digits, characterized by persistent periungual and subungual erythema, sterile pustules, significant nail plate dystrophy with thickening and fragmentation, and associated digital swelling, tenderness, and restricted motion. Prior therapies, including topical corticosteroids, phototherapy, and systemic tofacitinib, had proven ineffective. Diagnosis was confirmed clinically and supported by MRI, which revealed active bone marrow edema in the distal phalanges. The therapeutic intervention involved initial periungual injections of a diluted Xeligekimab formulation, which led to partial improvement. This was followed by a series of injections using undiluted Xeligekimab (100 mg/mL). This escalation resulted in marked clinical resolution: complete clearance of pustules and inflammation, healthy nail regrowth, and resolution of digital swelling and pain. Concurrently, the Dermatology Life Quality Index and pain scores dramatically improved, and follow-up MRI showed substantial resolution of the underlying bone marrow edema, confirming the treatment's efficacy on both cutaneous and deep osseous inflammation.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41853264 · DOI · PMC12992313

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Acrodermatitis enteropathica and an overview of zinc metabolism [5]
    Maverakis E, Fung MA, Lynch PJ, Draznin M, Michael DJ, Ruben B, et al. · J Am Acad Dermatol · 2007 · cited 189 times (Europe PMC)
  • Research article Skin Manifestations Associated with COVID-19: Current Knowledge and Future Perspectives [6]
    Genovese G, Moltrasio C, Berti E, Marzano AV · Dermatology · 2021 · cited 147 times (Europe PMC)
  • Research article An update on mutations of the SLC39A4 gene in acrodermatitis enteropathica [7]
    Schmitt S, Küry S, Giraud M, Dréno B, Kharfi M, Bézieau S · Hum Mutat · 2009 · cited 89 times (Europe PMC)
  • Research article Regulation and function of Zip4, the acrodermatitis enteropathica gene [8]
    Andrews GK · Biochem Soc Trans · 2008 · cited 84 times (Europe PMC)
  • Research article Acrodermatitis enteropathica: case report and review of the literature [9]
    Perafán-Riveros C, França LF, Alves AC, Sanches JA · Pediatr Dermatol · 2002 · cited 82 times (Europe PMC)
  • Research article Clinical and laboratory diagnosis of acrodermatitis enteropathica [10]
    Van Wouwe JP · Eur J Pediatr · 1989 · cited 59 times (Europe PMC)

References

  1. Stiles LI, Ferrao K, Mehta KJ. Role of zinc in health and disease. . 2024. PMID 38367035 · DOI · PMC10874324
  2. Pérez-Sala D, Oeste CL, Martínez AE, Carrasco MJ, Garzón B, Cañada FJ. Vimentin filament organization and stress sensing depend on its single cysteine residue and zinc binding. . 2015. PMID 26031447 · DOI · PMC4458873
  3. Geiser J, Venken KJ, De Lisle RC, Andrews GK. A mouse model of acrodermatitis enteropathica: loss of intestine zinc transporter ZIP4 (Slc39a4) disrupts the stem cell niche and intestine integrity. . 2012. PMID 22737083 · DOI · PMC3380849
  4. Cao P, Yuan A, Yang J, Zhang Y, Guo T, Li C. Case Report: Periungual Xeligekimab injection for refractory Acrodermatitis continua of Hallopeau. . 2026. PMID 41853264 · DOI · PMC12992313
  5. Maverakis E, Fung MA, Lynch PJ, Draznin M, Michael DJ, Ruben B, et al.. Acrodermatitis enteropathica and an overview of zinc metabolism. J Am Acad Dermatol. 2007. PMID 17190629 · DOI
  6. Genovese G, Moltrasio C, Berti E, Marzano AV. Skin Manifestations Associated with COVID-19: Current Knowledge and Future Perspectives. Dermatology. 2021. PMID 33232965 · DOI · PMC7801998
  7. Schmitt S, Küry S, Giraud M, Dréno B, Kharfi M, Bézieau S. An update on mutations of the SLC39A4 gene in acrodermatitis enteropathica. Hum Mutat. 2009. PMID 19370757 · DOI
  8. Andrews GK. Regulation and function of Zip4, the acrodermatitis enteropathica gene. Biochem Soc Trans. 2008. PMID 19021533 · DOI · PMC2634863
  9. Perafán-Riveros C, França LF, Alves AC, Sanches JA. Acrodermatitis enteropathica: case report and review of the literature. Pediatr Dermatol. 2002. PMID 12383101 · DOI
  10. Van Wouwe JP. Clinical and laboratory diagnosis of acrodermatitis enteropathica. Eur J Pediatr. 1989. PMID 2691254 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-29.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • Ectodermal DysplasiaRare and Inherited Diseases
  • Ehlers-Danlos SyndromeRare and Inherited Diseases
  • Epidermolysis BullosaRare and Inherited Diseases
  • IchthyosisRare and Inherited Diseases
  • Pseudoxanthoma ElasticumRare and Inherited Diseases
  • Xeroderma PigmentosumRare and Inherited Diseases

All 106 articles in Rare and Inherited Diseases →

At a glance

2,357
PubMed records on this heading
7%
published since 2020
278
review articles
1
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-29; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • Ectodermal DysplasiaRare and Inherited Diseases
  • Ehlers-Danlos SyndromeRare and Inherited Diseases
  • Epidermolysis BullosaRare and Inherited Diseases
  • IchthyosisRare and Inherited Diseases
  • Pseudoxanthoma ElasticumRare and Inherited Diseases

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support